The Barrett's Research Journal
The GLP-1 world moves fast, and keeping up can feel like a second job. So we do the reading for you — pricing shifts, FDA news, and the research that actually matters, explained in plain language. Nobody pays us for placement, and we'll always tell you the honest trade-offs.
The full library
Everything we've written for you
30 guides and updates on FDA decisions, real provider pricing, and the trial results worth knowing about — all in plain English.
Where to Find Affordable Compounded Semaglutide Online (Without the Guesswork) — June 2026
Compounded semaglutide — the same active molecule as Ozempic and Wegovy — starts around $99/month from licensed US telehealth providers. We dug into June 2026 pricing, pharmacy partners, credentialing, and shipping speed so you can find a trustworthy option without falling for a teaser rate.
Paying Less for Zepbound in 2026: 6 Honest Paths from $25 to $349 a Month
Zepbound lists at $1,089/month, but almost nobody pays that. Your real out-of-pocket cost can range from $25 with a savings card to $349 for self-pay vials to about $99 for compounded tirzepatide. We'll walk you through every legitimate way to reach its molecule for less — including the Mounjaro route a lot of people miss.
Affordable Compounded Tirzepatide Online: 6 Programs We'd Trust, Compared (May 2026)
Compounded tirzepatide — the same active ingredient in Zepbound and Mounjaro — is available from licensed US telehealth providers starting around $99/month. We checked pricing, pharmacy partners, credentialing, and shipping for the most affordable legitimate programs, and we'll show you how to compare them with confidence.
Staying on Semaglutide for the Long Haul: What 90,000 Patients Tell Us About Your Heart and Kidneys (May 2026)
New May 2026 research suggests GLP-1s cut major cardiovascular events by 13–26% and lower the risk of kidney disease and sleep apnea — but stepping away for just six months can erase much of that protection. Here's what data from more than 90,000 patients tells us about why staying on semaglutide matters.
Looking Beyond Wegovy in 2026: Alternatives That Fit Your Cost, Coverage, and Goals
Wegovy works — but it isn't the only road, and it isn't always the right one for your budget or your body. In 2026 the legitimate alternatives range from more potent (Zepbound vials around $349/mo) to gentler on the wallet ($149/mo oral pills, $99/mo compounded semaglutide) to more insurance-friendly (Mounjaro for diabetes). Here's how to find your fit.
Worried About Hair Loss on Zepbound? Here's the Reassuring Truth (2026)
About 5.7% of people on the highest Zepbound dose reported hair shedding in trials, with real-world telehealth rates running 8–12%. The good news: it's almost always temporary shedding driven by rapid weight loss, not the drug damaging your follicles. Here's why it happens and the simple steps that help.
Getting Mounjaro for $25 a Month: Who Qualifies and What to Do If You Don't (2026)
Eli Lilly's Mounjaro Savings Card can drop your copay to $25/month — but only for commercially insured patients with a type 2 diabetes diagnosis. We'll walk you through exactly who qualifies, how to enroll, what to do if your plan denies prior authorization, and the legitimate fallbacks if $25 isn't on the table for you.
How Long Do Zepbound Side Effects Really Last? A Gentle Timeline by Symptom (2026)
Most Zepbound side effects begin within 24–72 hours of an injection and ease within 1–2 weeks at each new dose. Nausea usually peaks first; fatigue and constipation can linger a little longer. Here's the realistic timeline by symptom — plus how to tell when it's simply your body adjusting versus a sign to slow down.
Zepbound and Mounjaro: Same Medicine, Different Label — and What That Means for Your Bill (2026)
Same molecule (tirzepatide), same maker (Eli Lilly), same dose strengths — but a different FDA label. Mounjaro is approved for type 2 diabetes; Zepbound for chronic weight management. That single difference quietly shapes your cost, your coverage, and the cheapest legitimate path open to you in 2026. Here's how to use it to your advantage.
Can You Stay on a Lower Dose of Wegovy Once You Hit Your Goal? (2026 Maintenance Guide)
Yes — and many people who reach their goal weight do exactly that. The FDA label lists 2.4 mg, but in real-world practice clinicians routinely maintain stable patients at 1.0–1.7 mg (sometimes lower). Here's what tends to work, what insurance will actually pay for, and which providers are flexible enough to customize your dose.
Zepbound or Wegovy: Which One Actually Fits You? A 2026 Head-to-Head
For many people, Zepbound wins on raw results — about 20% mean weight loss versus Wegovy's ~14% in the head-to-head SURMOUNT-5 trial. But cost, side effects, and the new $149/month oral pills can flip the answer for you specifically. Here's an honest 2026 breakdown to help you and your doctor choose.
GLP-1s and Hair Loss: What 84,000 Patients Reveal — and Why It's Usually Temporary (May 2026)
A 2026 meta-analysis of 84,000 GLP-1 users found a 3.4x higher hair-loss risk versus non-users. That sounds alarming — but the reassuring context matters: it's usually temporary shedding driven by rapid weight loss, it hits faster losers hardest, and good nutrition plus a steadier pace tend to stop it. Here's the full, calm picture.
GLP-1 Microdosing: An Honest Look at Whether It Works, What It Costs, and Who Offers It (2026)
GLP-1 microdosing — taking roughly 0.05–0.125 mg/week instead of the standard 0.25–2.4 mg — is having a moment online. We'll tell you honestly what clinicians actually say about it, who offers it, what it costs, and who it might (and might not) suit.
A New 'Gut Reset' Procedure May Help Lock In GLP-1 Weight Loss After You Stop (Early Study)
A new sham-controlled trial found that a minimally invasive gut procedure helped patients keep about 80% of their GLP-1 weight loss after stopping tirzepatide. It's early, hopeful data on the hardest problem in this whole field — keeping the weight off — and here's what it does and doesn't mean for you.
Quitting and Restarting Your GLP-1? What It Quietly Does to Your Muscle — and How to Protect It (2026)
Fewer than 1 in 4 people stay on a GLP-1 after a year, and up to 40% of the weight lost can be muscle — with each stop-and-restart cycle making things worse. It's a real concern, but a very manageable one. Here's what the research shows and the simple habits that protect your strength.
24 Million Americans Just Lost GLP-1 Coverage — Here's What Happened and What You Can Do
Reporting indicates about 12 million people lost Zepbound coverage and another 12 million lost Wegovy coverage over the past year, as CVS Caremark, BCBS Massachusetts, and Harvard Pilgrim all pulled back. If you were dropped, you're not alone — and you have immediate, legitimate options. Here's the full picture and your next steps.
Your Insurance Dropped Your GLP-1? The 5 Most Affordable Ways to Keep Going (2026)
An estimated 41 million Americans lost commercial GLP-1 coverage in 2026, with CVS Caremark dropping Zepbound and BCBS restricting Wegovy. If you're suddenly facing the full price, here are the five cheapest legitimate ways to keep your medication — explained simply, with the trade-offs laid out honestly.
Could Your Genes Predict How Well You'll Do on a GLP-1? A New Study Says Maybe
A large 23andMe study published in Nature identified genetic variants that seem to predict GLP-1 weight loss (a wide 6–20% range) and nausea risk (a striking 5–78% range). It's an early peek at a more personalized future — here's what it could eventually mean for choosing your medication.
Hims Is Phasing Out Compounded Semaglutide: What Its Novo Nordisk Deal Means for You
Hims partnered with Novo Nordisk, stopped advertising compounded GLP-1s, and now offers FDA-approved Wegovy starting around $149/month. If you're a current compounded customer, here's what's changing and how to plan a smooth transition rather than getting caught off guard.
Foundayo Is Shipping: How to Get Eli Lilly's GLP-1 Pill for $149 a Month
LillyDirect began shipping Foundayo on April 6, 2026. If you've been waiting for a needle-free option, here's exactly how to order it, what it costs with and without insurance, and how it stacks up against every other GLP-1 path — explained step by step.
Medicare's New GLP-1 Pilot, Explained: How the CMS Balance Model Works (April 2026)
CMS's new Balance Model launches in July 2026 as Medicare's first value-based GLP-1 coverage pilot. If you're on Part D, this could finally open an affordable door — here's what it is, who's eligible, and what to do now to be ready.
The 2026 GLP-1 Price War, Decoded: Foundayo $25, Wegovy $249, Compounded $99 — Every Option Ranked
Foundayo at $25/mo with insurance ($149 self-pay), Wegovy subscriptions at $249/mo, compounded tirzepatide from $99, Zepbound vials at $349, and a $50 Medicare Bridge arriving in July. Prices are finally falling — here's every legitimate 2026 GLP-1 option ranked by monthly cost, so you can find your best deal.
The FDA Just Approved Foundayo: The GLP-1 Pill You Can Take With Food (April 2026)
Eli Lilly's oral weight-loss pill earned one of the fastest FDA approvals in decades on April 1, 2026. If the strict rules of older oral semaglutide put you off, Foundayo's big advantage will get your attention — and so will the roughly $149/month self-pay price. Here's the rundown.
The GLP-1 Pill War Heats Up: What Orforglipron Means for You (April 2026)
Eli Lilly's oral GLP-1 faces its FDA decision on April 10, and Novo Nordisk just launched Wegovy subscriptions at $249/month. Competition like this usually means better prices and easier access for you — here's what the pill war means right now and what to watch for.
The Medicare GLP-1 Bridge: 5 Things to Get Ready Before July 2026
The $50/month Medicare GLP-1 Bridge launches July 1, 2026. If you're on Part D, a little preparation now could lock in affordable access to Wegovy, Zepbound, or Foundayo. Here are five simple things to sort out before the start date.
Oral Wegovy, Three Months In: What Real Users Are Telling Us (2026)
Three months after the December 2025 launch, early oral semaglutide users are reporting meaningful weight loss and a familiar side-effect profile — but one sticking point keeps coming up. Here's the honest, real-world picture of what to expect.
FDA Flags 12 More Compounding Pharmacies: What It Means If You're on a Compounded GLP-1 (March 2026)
The FDA's March 2026 enforcement wave added 12 more compounding pharmacies to its warning list, pushing the total past 40 since late 2025. If you rely on a compounded GLP-1, here's what it means for you and the simple checks worth doing now.
This Month's GLP-1 Price Check: Where the Best Deals Landed (March 2026)
We tracked pricing across the six GLP-1 programs we cover in March 2026 — who's cheapest to start, who's best for ongoing cost, and the trade-offs behind each headline number. Here's the honest monthly snapshot so you can choose well.
Orforglipron's April 10 FDA Decision: Why This Oral GLP-1 Could Be a Game-Changer (April 2026)
Eli Lilly's oral, non-peptide GLP-1 orforglipron faces its FDA decision on April 10, 2026. Because it's built differently from older oral semaglutide, it sidesteps the fasting hassles — and it could bring millions of needle-averse people into GLP-1 treatment. Here's what to know before decision day.
We've got your back
Something new to read every week
We keep watching FDA decisions, pricing moves, and fresh research, then translate it into plain language so you can walk into your next appointment feeling prepared, not overwhelmed.
Not sure which program is the right fit?
Answer six quick questions and we'll point you to the programs that suit your budget, your insurance, and how you want to be cared for.